Growth Hormone
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Value | £18,345,903 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Region | Scotland |
| Deadline | 21 Sept 2020 |
| Procedure | open |
| OCID | ocds-r6ebe6-0000612178 |
Awards (7)
This procurement was awarded to 7 suppliers. Values shown are per-award; the notice total is £18,345,903.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Eli Lilly & Company Limited shared | · | · | · |
| Ferring Pharmaceuticals Limited shared | · | · | · |
| Ipsen Limited shared | · | · | · |
| Merck Serono shared | · | · | · |
| Novo Nordisk Ltd shared | · | · | · |
| Pfizer Ltd shared | · | · | · |
| Sandoz Ltd shared | · | · | · |
description
The Framework Agreement is for the supply of Growth Hormone to health boards across NHS Scotland.
documents
- Growth Hormone , contractNotice
- Growth Hormone , awardNotice
Documents are linked, not mirrored. They are served by the publishing authority and may require registration.
more from The Common Services Agency (more commonly known as NHS National Services Scotland) ("NSS")
- Insulin Infusion Pumps, Continuous Glucose Monitoring Systems and Associated Consumables · £140,000,000 · 9 Jul 2026
- Central Venous Catheters · £13,000,000 · 2 Jun 2026
- Sack Holders · £1,303,000 · 16 Apr 2026
- Sack Holders · £1,303,000 · 16 Apr 2026
- GP IT Systems · £1,500,000 · 1 Apr 2026
- TB Molecular · £467,800 · 1 Apr 2026
- Automated AST & Bacteria Testing · £6,192,812 · 27 Mar 2026
- NP884925 Adobe Licence · £53,937 · 27 Mar 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Public Contracts Scotland. Contact details for named individuals are not reproduced on this site.